Irhythm Technologies (NASDAQ:IRTC) Downgraded by BidaskClub to Sell
Several other research firms have also commented on IRTC. Citigroup lowered their price target on shares of Irhythm Technologies from $120.00 to $112.00 and set a buy rating for the company in a research report on Friday, March 27th. Oppenheimer restated a hold rating on shares of Irhythm Technologies in a research report on Friday, May 8th. Morgan Stanley upped their price target on shares of Irhythm Technologies from $114.00 to $142.00 and gave the stock an overweight rating in a research report on Friday, May 8th. SunTrust Banks upped their price target on shares of Irhythm Technologies from $102.00 to $130.00 and gave the stock a buy rating in a research report on Friday, May 8th. Finally, Zacks Investment Research downgraded shares of Irhythm Technologies from a buy rating to a hold rating in a report on Wednesday, June 24th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $132.43.
IRTC stock opened at $114.97 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 3.60 and a quick ratio of 3.51. Irhythm Technologies has a 1-year low of $56.24 and a 1-year high of $136.55. The firm has a fifty day moving average price of $122.27 and a two-hundred day moving average price of $93.15. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -52.50 and a beta of 1.42.
In other Irhythm Technologies news, CEO Kevin M. King sold 72,000 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $125.62, for a total value of $9,044,640.00. Following the completion of the sale, the chief executive officer now directly owns 240,674 shares of the company’s stock, valued at approximately $30,233,467.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ralph Snyderman sold 250 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $134.55, for a total transaction of $33,637.50. Following the completion of the sale, the director now directly owns 4,256 shares of the company’s stock, valued at $572,644.80. The disclosure for this sale can be found here. Insiders sold 141,862 shares of company stock valued at $17,677,502 in the last ninety days. Corporate insiders own 3.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of IRTC. Cornerstone Advisors Inc. lifted its holdings in Irhythm Technologies by 53.8% in the 1st quarter. Cornerstone Advisors Inc. now owns 426 shares of the company’s stock valued at $35,000 after acquiring an additional 149 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in Irhythm Technologies in the 4th quarter valued at about $90,000. Great West Life Assurance Co. Can lifted its holdings in Irhythm Technologies by 16.4% in the 4th quarter. Great West Life Assurance Co. Can now owns 1,653 shares of the company’s stock valued at $112,000 after acquiring an additional 233 shares during the last quarter. Strs Ohio acquired a new stake in Irhythm Technologies during the 1st quarter worth about $113,000. Finally, Exchange Traded Concepts LLC raised its holdings in Irhythm Technologies by 23.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,543 shares of the company’s stock worth $126,000 after buying an additional 297 shares during the period.
Irhythm Technologies Company Profile
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Read More: Blue-Chip Stocks
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.